Cancer-Focused BridgeBio's $949M SPAC Deal Gets SEC Nod

By Jade Martinez-Pogue
July 11, 2025, 4:25 PM EDT

Clinical-stage biopharmaceutical company BridgeBio Oncology Therapeutics, advised by Goodwin Procter LLP, and White & Case LLP-led special purpose acquisition company Helix Acquisition Corp. II on Friday revealed that their $949 million merger...

Already a subscriber? Click here to view full article